MX2022008626A - Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea. - Google Patents

Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.

Info

Publication number
MX2022008626A
MX2022008626A MX2022008626A MX2022008626A MX2022008626A MX 2022008626 A MX2022008626 A MX 2022008626A MX 2022008626 A MX2022008626 A MX 2022008626A MX 2022008626 A MX2022008626 A MX 2022008626A MX 2022008626 A MX2022008626 A MX 2022008626A
Authority
MX
Mexico
Prior art keywords
thyroid hormone
receptor agonists
hormone receptor
substituted triazinones
triazinones
Prior art date
Application number
MX2022008626A
Other languages
English (en)
Spanish (es)
Inventor
Jiuxiang Zhu
Jingye Zhou
Mingwei Zheng
Original Assignee
Eccogene Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eccogene Shanghai Co Ltd filed Critical Eccogene Shanghai Co Ltd
Publication of MX2022008626A publication Critical patent/MX2022008626A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2022008626A 2020-01-13 2021-01-13 Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea. MX2022008626A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020071741 2020-01-13
CN2020107757 2020-08-07
PCT/CN2021/071381 WO2021143706A1 (en) 2020-01-13 2021-01-13 Substituted triazinones as thyroid hormone receptor agonists

Publications (1)

Publication Number Publication Date
MX2022008626A true MX2022008626A (es) 2022-08-22

Family

ID=74418122

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008626A MX2022008626A (es) 2020-01-13 2021-01-13 Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.

Country Status (9)

Country Link
US (3) US11780825B2 (cg-RX-API-DMAC7.html)
EP (1) EP4090652A1 (cg-RX-API-DMAC7.html)
JP (1) JP7728265B2 (cg-RX-API-DMAC7.html)
CN (1) CN115244037B (cg-RX-API-DMAC7.html)
AU (1) AU2021208027B2 (cg-RX-API-DMAC7.html)
IL (1) IL294494A (cg-RX-API-DMAC7.html)
MX (1) MX2022008626A (cg-RX-API-DMAC7.html)
WO (1) WO2021143706A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202207541B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
MX2022008626A (es) 2020-01-13 2022-08-22 Eccogene Shanghai Co Ltd Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
JP2023549332A (ja) * 2020-11-06 2023-11-24 アリゴス セラピューティクス,インコーポレーテッド 甲状腺ホルモン受容体調節剤としての2-ピリドン
CN114685450B (zh) * 2020-12-30 2026-06-16 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
CN117624069A (zh) * 2022-08-19 2024-03-01 凯思凯迪(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途
CN118146123A (zh) * 2024-02-04 2024-06-07 河北鼎泰制药有限公司 一种盐酸安罗替尼中间体的合成方法
WO2026067791A1 (en) * 2024-09-30 2026-04-02 Ascletis Pharma (China) Co., Limited 2-phenyl-1,2,4-triazine-3,5(2h,4h)-dione derivatives as thr-beta agonist or modulators for the treatment of obesity
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE60020786T2 (de) 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
ES2267945T3 (es) 2001-05-31 2007-03-16 Pfizer Products Inc. Uso medico de compuestos tiromimeticos para tratar la perdida del cabello y composiciones.
ATE480524T1 (de) 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
KR101396606B1 (ko) * 2009-04-20 2014-05-16 미쓰비시 타나베 파마 코퍼레이션 신규 갑상선 호르몬 β 수용체 작동약
JP5847533B2 (ja) * 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
CN109574995B (zh) 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
CN119431265A (zh) * 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
MX2022008626A (es) 2020-01-13 2022-08-22 Eccogene Shanghai Co Ltd Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
EP4167986A4 (en) * 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS

Also Published As

Publication number Publication date
CA3164404A1 (en) 2021-07-22
US12291518B2 (en) 2025-05-06
KR20220128383A (ko) 2022-09-20
WO2021143706A1 (en) 2021-07-22
JP7728265B2 (ja) 2025-08-22
IL294494A (en) 2022-09-01
CN115244037B (zh) 2024-10-25
US20250320197A1 (en) 2025-10-16
CN115244037A (zh) 2022-10-25
JP2023510835A (ja) 2023-03-15
AU2021208027B2 (en) 2025-10-16
US20240190846A1 (en) 2024-06-13
US20210230146A1 (en) 2021-07-29
US11780825B2 (en) 2023-10-10
EP4090652A1 (en) 2022-11-23
ZA202207541B (en) 2024-12-18
AU2021208027A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
ZA202207541B (en) Substituted triazinones as thyroid hormone receptor agonists
PH12023550130A1 (en) Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same
EP4523747A3 (en) Glp-1r receptor agonist compound and use thereof
MY207657A (en) Thr receptor agonist compound and preparation method and use thereof
CR9910A (es) Antagonistas del receptor 3 de la histamina
MX2023001812A (es) Compuestos del acido azociclohexil acetico sustituidos por triazol-piridinilo como antagonistas del receptor lpa.
AR111570A1 (es) Composición farmacéutica que comprende selexipag
BR0314126A (pt) Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio
BR112012023178A2 (pt) ramidinas substituídas como antagonistas de receptor prostaglandina 2
WO2020081410A3 (en) Radioligands for imaging the lpa1 receptor
ZA202002762B (en) Benzimidazole derivatives and their uses
CR20210375A (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
PH12021552004A1 (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
MX2021009570A (es) Compuestos biciclicos sustituidos como moduladores del receptor de farnesoide x.
WO2022099060A3 (en) Bicyclic pyridazinones as thyroid hormone receptor beta (tr-beta) agonists
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
JOP20200079A1 (ar) مثبطات مستقبل عامل نمو البشرة
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
MX2024010344A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
BR112022009533A2 (pt) Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica
MX2024002892A (es) Azalidos inmunomoduladores.
GEP20257771B (en) Compounds and compositions as sppl2a inhibitors
NZ774113A (en) Dp antagonist
EA202190339A1 (ru) Пиридопиримидины в качестве ингибиторов н4-гистаминовых рецепторов